➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
Merck
Boehringer Ingelheim
Moodys
McKinsey

Last Updated: May 8, 2021

DrugPatentWatch Database Preview

APTIVUS Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Aptivus, and when can generic versions of Aptivus launch?

Aptivus is a drug marketed by Boehringer Ingelheim and is included in two NDAs.

The generic ingredient in APTIVUS is tipranavir. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the tipranavir profile page.

Drug patent expirations by year for APTIVUS
Drug Prices for APTIVUS

See drug prices for APTIVUS

Recent Clinical Trials for APTIVUS

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Boehringer IngelheimPhase 3
National Institute of Mental Health (NIMH)Phase 2/Phase 3
National Institutes of Health (NIH)Phase 2/Phase 3

See all APTIVUS clinical trials

Pharmacology for APTIVUS
Drug ClassProtease Inhibitor
Mechanism of ActionHIV Protease Inhibitors

US Patents and Regulatory Information for APTIVUS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Boehringer Ingelheim APTIVUS tipranavir CAPSULE;ORAL 021814-001 Jun 22, 2005 RX Yes Yes   Get Started for $10   Get Started for $10   Get Started for $10
Boehringer Ingelheim APTIVUS tipranavir SOLUTION;ORAL 022292-001 Jun 23, 2008 RX Yes Yes   Get Started for $10   Get Started for $10   Get Started for $10
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for APTIVUS

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Boehringer Ingelheim APTIVUS tipranavir SOLUTION;ORAL 022292-001 Jun 23, 2008   Get Started for $10   Get Started for $10
Boehringer Ingelheim APTIVUS tipranavir CAPSULE;ORAL 021814-001 Jun 22, 2005   Get Started for $10   Get Started for $10
Boehringer Ingelheim APTIVUS tipranavir CAPSULE;ORAL 021814-001 Jun 22, 2005   Get Started for $10   Get Started for $10
Boehringer Ingelheim APTIVUS tipranavir CAPSULE;ORAL 021814-001 Jun 22, 2005   Get Started for $10   Get Started for $10
Boehringer Ingelheim APTIVUS tipranavir SOLUTION;ORAL 022292-001 Jun 23, 2008   Get Started for $10   Get Started for $10
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for APTIVUS

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0758327 C00758327/01 Switzerland   Get Started for $10 FORMER REPRESENTANTIVE: E. BLUM AND CO. PATENTANWAELTE, CH
0758327 SPC/GB06/009 United Kingdom   Get Started for $10 PRODUCT NAME: (R-(R*,R*))-N-(3-(1-(5,6-DIHYDRO-4-HYDROXY-2-OXO-6-(2-PHENYLETHYL)-6-PROPYL-2H-PYRAN-3-YL)PROPYL)PHENYL)-5-(TRIFLUOROMETHYL)-2-PYRIDINESULFONAMIDE OR A PHARMACEUTICAL SALT THEREOF = (TIPRANAVIR OR A PHARMACEUTICAL SALT THEREOF); REGISTERED: CH 57330 20050825; UK EU/1/05/315/001 20051025
0758327 05C0047 France   Get Started for $10 PRODUCT NAME: TIPRANAVIR; REGISTRATION NO/DATE: EU/1/05/315/001 20051025
0758327 SPC034/2005 Ireland   Get Started for $10 SPC034/2005: 20061023, EXPIRES: 20200503
0758327 PA2005008 Lithuania   Get Started for $10 PRODCT NAME: TIPRANAVIRUM; REGISTRATION NO/DATE: EU/1/05/315/001 20051025
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Colorcon
McKinsey
Johnson and Johnson
Express Scripts
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.